Iovance Biotherapeutics to Present at Upcoming Investor Conferences in November
November 07 2019 - 3:32PM
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage
biotechnology company developing novel cancer immunotherapies based
on tumor-infiltrating lymphocyte (TIL) technology, today announced
that the company plans to present at the following conferences in
November:
- Cowen's 3rd Annual IO Next Summit in Maryland,
Nov. 8, 2019Location: Gaylord National Resort and Convention
CenterDate/Time: Friday, Nov. 8, at 9:30 a.m. EST
- Credit Suisse 28th Annual Healthcare
Conference in Scottsdale, Ariz., Nov. 11-13, 2019Location:
The Phoenician, ScottsdaleDate/Time: Tuesday, Nov. 12, at 4:45 p.m.
MST
- Stifel 2019 Healthcare Conference in New York,
Nov. 19-21, 2019Location: Lotte New York Palace HotelDate/Time:
Tuesday, Nov. 19, at 4:45 p.m. EST
- Jefferies 2019 London Healthcare Conference in
London, Nov. 20-21, 2019Location: The Waldorf Hilton,
LondonDate/Time: Thursday, Nov. 21, at 9:20 a.m. GMT
Live and archived webcasts of the presentations will be
available in the Investors section of the Iovance website at
http://ir.iovance.com.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics intends to improve patient care by making T
cell-based immunotherapies broadly accessible for the treatment of
patients with solid tumors and blood cancers. Tumor infiltrating
lymphocyte (TIL) therapy uses a patient’s own immune cells to
attack cancer. TIL cells are extracted from a patient’s own tumor
tissue, expanded through a proprietary process, and infused back
into the patient. After infusion, TIL reach tumor tissue, where
they attack tumor cells. The company is currently conducting
pivotal studies in patients with metastatic melanoma and advanced
cervical cancer. In addition, the company’s TIL therapies are being
investigated for the treatment of patients with locally advanced,
recurrent or metastatic cancers including head and neck and
non-small cell lung cancer. Clinical studies of T cell therapy for
blood cancers called peripheral blood lymphocyte (PBL) therapy are
being planned. For more information, please visit
www.iovance.com.
Forward-Looking Statements
Certain matters discussed in this press release are
“forward-looking statements” of Iovance Biotherapeutics, Inc.
(hereinafter referred to as the “Company,” “we,” “us,” or “our”).
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “continue,” “estimates,” “anticipates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “will,” “should” or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. The forward-looking
statements include, but are not limited to, risks and uncertainties
relating to the success, timing, projected enrollment,
manufacturing and production capabilities, and cost of our ongoing
clinical trials and anticipated clinical trials for our current
product candidates (including both Company-sponsored and
collaborator-sponsored trials in both the U.S. and Europe), such as
statements regarding the timing of initiation and completion of
these trials; the timing of and our ability to successfully submit,
obtain and maintain FDA or other regulatory authority approval of,
or other action with respect to, our product candidates, including
those product candidates that have been granted breakthrough
therapy designation (“BTD”) or regenerative medicine advanced
therapy designation (“RMAT”) by the FDA and new product candidates
in both solid tumor and blood cancers; the strength of the
Company’s product pipeline; the successful implementation of the
Company’s research and development programs and collaborations; the
Company’s ability to obtain tax incentives and credits; the
guidance provided for the Company’s future cash, cash equivalent,
and short term investment positions; the success of the Company’s
manufacturing, license or development agreements; the acceptance by
the market of the Company’s product candidates, if approved; and
other factors, including general economic conditions and regulatory
developments, not within the Company’s control. The factors
discussed herein could cause actual results and developments to be
materially different from those expressed in or implied by such
statements. Actual results may differ from those set forth in this
press release due to the risks and uncertainties inherent in the
Company’s business, including, without limitation: the preliminary
clinical results, which may include efficacy and safety results,
from ongoing Phase 2 studies may not be reflected in the final
analyses of these trials; the rate of enrollment may impact the
Company’s clinical trial timelines; enrollment may need to be
adjusted for the Company’s trials and cohorts within those trials
based on FDA and other regulatory agency input; the new version of
the protocol which further defines the patient population to
include more advanced patients in the Company’s cervical cancer
trial may have an adverse effect on the results reported to date;
the data within these trials may not be supportive of product
approval; changes in patient populations may result in changes in
preliminary clinical results; the Company’s ability to address FDA
or other regulatory authority requirements relating to its clinical
programs and registrational plans, such requirements including, but
not limited to, clinical, safety, manufacturing and control
requirements; the Company’s interpretation of communications with
the FDA; risks related to the Company’s ability to maintain and
benefit from accelerated FDA review designations, including BTD and
RMAT, which may not result in a faster development process or
review of the Company’s product candidates (and which may later be
rescinded by the FDA), and does not assure approval of such product
candidates by the FDA or the ability of the Company to obtain FDA
approval in time to benefit from commercial opportunities; and the
ability of the Company to manufacture its therapies using third
party manufacturers. A further list and description of the
Company’s risks, uncertainties and other factors can be found in
the Company’s most recent Annual Report on Form 10-K and the
Company’s subsequent filings with the Securities and Exchange
Commission. Copies of these filings are available online at
www.sec.gov or www.iovance.com. The forward-looking statements are
made only as of the date of this press release and the Company
undertakes no obligation to publicly update such forward-looking
statements to reflect subsequent events or circumstances.
Investor Relations Contacts: Annie
ChangSolebury Trout646-378-2972achang@troutgroup.com
Chad RubinSolebury Trout646-378-2947crubin@troutgroup.com
Media Relations Contact: Rich AllanSolebury
Trout646-378-2958rallan@troutgroup.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Apr 2024 to May 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From May 2023 to May 2024